Uncategorized
BPC-157 Research
BPC-157 – Research Overview: Mechanisms, Study Data & Laboratory Application
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids. First isolated by Croatian researchers in the 1990s as the bioactive fragment of a naturally occurring gastric protection protein, BPC-157 has become one of the most studied peptides in preclinical science – particularly across gastrointestinal biology, tissue signaling, and cellular regeneration pathways.
This article provides a structured, evidence-based overview of the current research landscape surrounding BPC-157. All compounds on this site are supplied exclusively for controlled laboratory research (research use only).
What Is BPC-157?
BPC-157 is a pentadecapeptide with the amino acid sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (CAS No. 137525-51-0). The molecule was characterized as the bioactive fragment of Body Protection Compound (BPC), a protein naturally present in trace amounts in human gastric juice.
One of its most notable properties is exceptional chemical stability: BPC-157 remains intact in gastric fluid for over 24 hours, while most peptides are hydrolyzed within minutes (Sikiric et al., 2011). This makes it a particularly useful reference compound in laboratory models studying peptide behavior under physiological conditions.
Primary Research Domains
Gastrointestinal Signaling
The gastrointestinal tract represents the best-documented research area for BPC-157. Early comparative studies in preclinical ulcer models demonstrated consistent activity across the entire GI tract – from esophagus and stomach through intestine, liver, and pancreas. BPC-157 was subsequently designated as PL-14736 for IBD-related clinical research programs, underscoring its translational relevance.
Tissue Structure & Cell Signaling
Multiple laboratory studies examine how BPC-157 interacts with fibroblasts, collagen synthesis, and cell migration pathways. A systematic review covering 36 studies (1993–2024) summarized preclinical findings in the orthopedic and sports medicine context, noting consistently positive structural outcomes in musculoskeletal injury models.
Vascular & Inflammatory Mechanisms
Research focuses on BPC-157’s modulation of the nitric oxide system (NO synthase), inhibition of pro-inflammatory cytokines, and promotion of angiogenesis – all central to ongoing cytoprotective laboratory investigations.
Neuroprotective Research
More recent laboratory models explore potential neuroprotective properties of BPC-157, including effects on peripheral nerve injury models and interactions within dopaminergic signaling pathways.
Current Study Landscape (2026)
The large majority of available data derives from preclinical animal and cell models. Large-scale randomized controlled human trials remain outstanding.
- 2021 – Knee pain pilot (n=16): 87.5% reported symptom improvement after 6–12 months. No control group; evidence quality limited.
- 2024 – Interstitial cystitis study (n=12): 80–100% symptom reduction reported. No control arm.
- 2025 – IV safety study (n=2): Tolerability documented up to 20 mg IV. Too small for efficacy conclusions.
BPC-157 holds no approved drug status in the EU or Germany.
Evidence Grade at ISOLITE
Within the ISOLITE Peptides Research Hub, BPC-157 is classified at ★★★ Moderate: predominantly preclinical data, small human case series, no randomized controlled human trials currently available.
→ View the full evidence overview in the ISOLITE Research Hub
Laboratory Handling & Reconstitution
BPC-157 is typically supplied as a lyophilized powder and reconstituted with Bacteriostatic Water (BAC Water) for laboratory use. Use the ISOLITE Peptide Tools for precise concentration and dosing calculations:
→ Open the ISOLITE Peptide Tools Calculator
Legal Notice
BPC-157 is not approved as a medicinal product in Germany or the European Union. All ISOLITE products are intended exclusively for controlled in vitro laboratory research. Procurement is restricted to qualified researchers and licensed laboratory facilities.
References
- Sikiric et al. (2011) – PubMed / MEDLINE
- ClinicalTrials.gov – Search: PL-14736
- ISOLITE Research Hub
This article is for scientific information only. It does not constitute medical advice.
